+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neuropathic Pain"

Gabapentin Market - Forecasts from 2024 to 2029 - Product Thumbnail Image

Gabapentin Market - Forecasts from 2024 to 2029

  • Report
  • January 2024
  • 144 Pages
  • Global
From
From
From
Neuropathic Pain - Epidemiology Forecast to 2032 - Product Thumbnail Image

Neuropathic Pain - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Peripheral Neuropathic Pain - Epidemiology Forecast to 2032 - Product Thumbnail Image

Peripheral Neuropathic Pain - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Chronic Neuropathic Pain - Epidemiology Forecast to 2032 - Product Thumbnail Image

Chronic Neuropathic Pain - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
Gabapentin Market Report and Forecast 2023-2031 - Product Thumbnail Image

Gabapentin Market Report and Forecast 2023-2031

  • Report
  • July 2023
  • 140 Pages
  • Global
From
Analgesics Market Report and Forecast 2023-2031 - Product Thumbnail Image

Analgesics Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
Pregabalin Market 2022-2026 - Product Thumbnail Image

Pregabalin Market 2022-2026

  • Report
  • September 2022
  • 120 Pages
  • Global
From
From
From
From
From
From
From
From
From
Loading Indicator

Neuropathic pain is a type of chronic pain caused by damage to the nervous system. It is often described as a burning, tingling, or shooting sensation. Analgesics are medications used to reduce or eliminate pain. Neuropathic pain is often treated with a combination of analgesics, including non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and anticonvulsants. Other treatments may include physical therapy, nerve blocks, and electrical stimulation. The neuropathic pain market is a rapidly growing segment of the analgesics market. It is driven by the increasing prevalence of chronic pain conditions, such as diabetes, cancer, and multiple sclerosis. The market is expected to benefit from the development of novel treatments, such as gene therapy and stem cell therapy. Some companies in the neuropathic pain market include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, and Eli Lilly. Show Less Read more